Allos Therapeutics, Inc. Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at American Society of Clinical Oncology 2009

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that updated data from its pivotal Phase 2 PROPEL study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Orlando, Fla., from May 29 to June 2, 2009.

Back to news